pp-275 Injection
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Atopic dermatitis, Chronic obstructive airway disease, Asthma
Clinical stage: Phase 3
Modality: Peptide
Mechanism & Target: TSLP gene modulator
Route & form: SC injection
Differentiation: it is a TSLP antibody antagonist with high potency. The Phase I data has demonstrated favorable safety profile and tolerability in each dosage group.
Manufacturer #39685
A clinical-stage biopharmaceutical company focused on oncology. Developing a biologic therapeutic targeting oncology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None